Optimizing The Drug-Like Properties Of Leads In Drug Discovery [With CD-ROM]-..

Código: 1015827 Marca: Springer Publishing

R$ 1.825,92

até 4x de R$ 456,48 sem juros

ou R$ 1.734,62 via Pix

Qtde: Adicionar ao carrinho Disponibilidade: 45 dias úteis Estoque: 207 unidades

Parcelas
- 1x de R$ 1.825,92 sem juros
- 2x de R$ 912,96 sem juros
- 3x de R$ 608,64 sem juros
- 4x de R$ 456,48 sem juros
R$ 1.734,62
R$ 1.825,92

Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e., discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, "drug-like" properties refer to the molecule's physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.

ISBN	9780387340562
Autor(a)	Borchardt, Ronald
Editora	Springer Publishing
Ano de edição	2006
Páginas	512
Acabamento	Pacote (Pack)